These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 31504343

  • 1. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients.
    Verstockt B, Mertens E, Dreesen E, Outtier A, Noman M, Tops S, Schops G, Van Assche G, Vermeire S, Gils A, Ferrante M.
    J Crohns Colitis; 2020 Mar 13; 14(3):332-341. PubMed ID: 31504343
    [Abstract] [Full Text] [Related]

  • 2. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F.
    United European Gastroenterol J; 2021 Apr 13; 9(3):398-406. PubMed ID: 33203339
    [Abstract] [Full Text] [Related]

  • 3. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I.
    J Crohns Colitis; 2017 Aug 01; 11(8):921-929. PubMed ID: 28333288
    [Abstract] [Full Text] [Related]

  • 4. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, Phan BL, Hyams JS, Dubinsky MC.
    Inflamm Bowel Dis; 2016 Sep 01; 22(9):2121-6. PubMed ID: 27542130
    [Abstract] [Full Text] [Related]

  • 5. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
    Moens A, Verstockt B, Alsoud D, Sabino J, Ferrante M, Vermeire S.
    Inflamm Bowel Dis; 2022 Aug 01; 28(8):1135-1142. PubMed ID: 34751766
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
    Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M.
    Inflamm Bowel Dis; 2018 Oct 12; 24(11):2442-2451. PubMed ID: 29788318
    [Abstract] [Full Text] [Related]

  • 7. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
    Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV, Sands BE, Colombel JF, Dulai PS, Ungaro R.
    Clin Gastroenterol Hepatol; 2019 Nov 12; 17(12):2497-2505.e1. PubMed ID: 30625408
    [Abstract] [Full Text] [Related]

  • 8. Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease.
    Jossen J, Kiernan BD, Pittman N, Dubinsky MC.
    J Pediatr Gastroenterol Nutr; 2020 Mar 12; 70(3):304-309. PubMed ID: 31738290
    [Abstract] [Full Text] [Related]

  • 9. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
    Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, Kim ES, Jung Y, Eun CS, Kim TO, Kang SB, Kim YS, Seo GS, Lee CK, Im JP, Park SJ, Park DI, Ye BD.
    Inflamm Bowel Dis; 2021 Nov 15; 27(12):1931-1941. PubMed ID: 33501935
    [Abstract] [Full Text] [Related]

  • 10. Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.
    Yarur AJ, Bruss A, Naik S, Beniwal-Patel P, Fox C, Jain A, Berens B, Patel A, Ungaro R, Bahur B, Dubinsky M, Stein DJ.
    Dig Dis Sci; 2019 Jun 15; 64(6):1651-1659. PubMed ID: 30835029
    [Abstract] [Full Text] [Related]

  • 11. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
    Dragoni G, Bagnoli S, Le Grazie M, Campani C, Rogai F, Manetti N, Bensi C, Macrì G, Galli A, Milla M.
    J Dig Dis; 2019 May 15; 20(5):235-242. PubMed ID: 30927309
    [Abstract] [Full Text] [Related]

  • 12. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F.
    J Crohns Colitis; 2020 Sep 16; 14(9):1190-1201. PubMed ID: 32100016
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
    D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Sandborn WJ, Dornic Q, Lindner D, Kisfalvi K, Marins EG, Vermeire S.
    Eur J Gastroenterol Hepatol; 2024 Apr 01; 36(4):404-415. PubMed ID: 38417060
    [Abstract] [Full Text] [Related]

  • 14. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).
    Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T.
    Scand J Gastroenterol; 2018 Feb 01; 53(2):158-167. PubMed ID: 29258369
    [Abstract] [Full Text] [Related]

  • 15. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN.
    Clin Gastroenterol Hepatol; 2021 Jul 01; 19(7):1366-1376.e2. PubMed ID: 32668338
    [Abstract] [Full Text] [Related]

  • 16. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
    Bor R, Fábián A, Matuz M, Szepes Z, Farkas K, Miheller P, Szamosi T, Vincze Á, Rutka M, Szántó K, Bálint A, Nagy F, Milassin Á, Tóth T, Zsigmond F, Bajor J, Müllner K, Lakner L, Papp M, Salamon Á, Horváth G, Sarang K, Schäfer E, Sarlós P, Palatka K, Molnár T.
    Expert Opin Biol Ther; 2020 Feb 01; 20(2):205-213. PubMed ID: 31782939
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent.
    Fumery M, Serrero M, Bouguen G, Amiot A, Altwegg R, Nachury M, Vuitton L, Treton X, Caillo L, Pereira B, Buisson A.
    J Crohns Colitis; 2024 Oct 15; 18(10):1615-1621. PubMed ID: 38742654
    [Abstract] [Full Text] [Related]

  • 20. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
    Ungaro RC, Yarur A, Jossen J, Phan BL, Chefitz E, Sehgal P, Kamal K, Bruss A, Beniwal-Patel P, Fox C, Patel A, Bahur B, Jain A, Stein D, Naik S, Dubinsky MC.
    J Crohns Colitis; 2019 Aug 14; 13(8):963-969. PubMed ID: 31087100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.